Herbalife stock has delivered a steep decline of about 76.5% over the past five years, yet on current checks it still screens as cheap on several valuation measures. Recent shorter term returns have stabilised somewhat, so the key issue for investors is whether the current price already reflects the pressure that long term holders have felt.
-
Over the last five years, Herbalife shares are down about 76.5%, which leaves current investors weighing whether the market has already priced in the bulk of the damage.
-
Future valuation can hinge on Herbalife's ability to sustain its direct selling model and cash generation, while any pressure on distributor engagement or regulatory scrutiny may limit how much investors are willing to pay for the stock.
-
On Simply Wall St's broader checks, Herbalife screens as cheap in most tests, and the value score of 5 signals that the overall picture leans toward undervalued rather than fully priced.
The stock's next move may depend on whether Herbalife's fundamentals and risk profile justify the discount that the valuation checks are currently suggesting.
Compare Herbalife's deep value profile with hand picked 45 high quality undervalued stocks that also combine depressed long term returns with stronger fundamentals.
Is Herbalife a Bargain on Earnings?
The P/E ratio is a useful way to judge what the market is currently paying for Herbalife earnings. Herbalife shares trade on a P/E of about 7.9x, which is well below the Personal Products industry average of roughly 19.1x and also below the peer group average of about 13.2x.
Simply Wall St's fair P/E ratio for Herbalife is 22.3x, based on its assessment of the company profile and risks. That is much higher than the current 7.9x level, which points to a wide gap between what the market pays today and what this framework suggests could be justified if conditions supported it.
On this earnings multiple, Herbalife stock appears undervalued compared with both its industry and the fair P/E benchmark.
See what the numbers say about this price — find out in our valuation breakdown.
The Herbalife Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where Herbalife's valuation puzzle leaves off by explaining which paths for growth, margins and earnings would need to occur for the stock to be worth materially more or less than it is today, based on views shared on the Community page. Each one links its number to a specific view on how Herbalife's growth, profitability and risks could evolve, giving you something concrete to refer back to as new information becomes available.
The Herbalife community is split between a recovery story built on execution and technology and a more cautious view focused on structural pressures and regulation.
Bull case: 27% undervalued
"Herbalife's transformation into a next-generation, data-driven wellness company, including its investments in product innovation and personalized technology platforms, positions it to capitalize on the major secular trend of rising consumer demand for personalized and preventative health solutions, potentially leading to increased revenue and higher customer retention…"
Read the full Bull Case to see why Herbalife could be undervalued
Bear case: 38% overvalued
"Growing regulatory investigations into multi-level marketing practices and nutritional supplement health claims are expected to intensify globally over the next several years, leading to mounting compliance costs, disruptions in existing distributor networks, and the real risk of market access restrictions, all of which would weigh heavily on future revenue growth and profitability…"
Read the full Bear Case to see why Herbalife could be overvalued
Do you think there's more to the story for Herbalife? Head over to our Community to see what others are saying!
The Bottom Line
Herbalife screens as undervalued on earnings multiples, yet that discount only helps if the business can maintain its direct selling model and cash generation under regulatory and competitive pressure. The high overall value checks point to room for a re rating if confidence in the business improves, but they also highlight how much hinges on execution from here. The crux for investors is whether the current discount reflects a value opportunity or a value trap if distributor engagement or regulatory outcomes break the wrong way.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include HLF .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
